Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

‘Brisk iPhone sales to buoy lens module makers 2H22 revenue’ -DigiTimes Alert

Brisk sales of Apple's iPhone 14 Pro are expected to buoy related lens module makers' sales performance in the second half of 2022, according to market sources.

byBenzinga Newsdesk

September 29, 2022

1 minute read

Brisk sales of Apple’s iPhone 14 Pro are expected to buoy related lens module makers’ sales performance in the second half of 2022, according to market sources.

Biohaven And Pfizer Enter Strategic Collaboration For The Commercialization Of Rimegepant Outside The United States

By Benzinga Newsdesk

Today, 8:26 PM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Pfizer Inc. (NYSE:PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.

BHVN

Needham Maintains Buy on Lam Research, Raises Price Target to $325

By Vick Meyer

Today, 8:26 PM

Needham maintains Lam Research (NASDAQ:LRCX) with a Buy and raises the price target from $280 to $325.

LRCX

FDA
News

CytRx Comments On Orphazyme Complete Response Letter From FDA

By Benzinga Newsdesk

Today, 8:26 PM

CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S

CYTR